Sector Experts

Mara Goldstein

Cantor Fitzgerald

Image: Mara Goldstein

Mara Goldstein joined Cantor Fitzgerald & Co. from Thomson Reuters, where she served as director of research for Reuters Insight. Goldstein was initially responsible for the firm's healthcare research practice, and later assumed responsibility for all research activities and sectors. Prior to that, Goldstein was an executive director and senior pharmaceutical analyst at CIBC World Markets. At Cantor, Goldstein covers the biotechnology sector. Goldstein also worked at Alex Brown & Sons and CS First Boston. She holds a bachelor's degree in economics from Purdue University.




Recent Interviews

2015 Small-Cap Biotech Watchlist Announced (12/18/14) In its third year, The Life Sciences Report's 2015 Small-Cap Biotech Watchlist currently includes 12 drug development companies selected by leading analysts in the sector. With catalysts on the horizon and pipelines that encompass a variety of indications and innovative platforms, these biotechs are primed to return multiples on investment.

Catalysts Drive These Stocks: Mara Goldstein (2/20/14) Whether biotech stocks keep up the scorching pace of 2013 remains to be seen, but we can count on one thing going forward, says Cantor Fitzgerald Senior Analyst Mara Goldstein. We are still in a catalyst-driven market. In this interview with The Life Sciences Report, Goldstein discusses four names with approaching milestones that she believes are important growth drivers. Her fifth pick is a binary event story, meaning it could skyrocket on good data or plummet on bad.

Biotech Watchlist 2014: Sound Science, Innovative Ideas and a Sprinkle of Pixie Dust (1/15/14) stethbillfold82142013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative partnerships and the overall market upswing. The 2013 Biotech Watchlist, which was released at the Biotech Showcase in San Francisco, reflected this robustness, boasting a year-to-date return that blew past those posted by the major indices. Credit the basket of stocks picked by industry experts, weighted heavily with winners. Can our panel of experts pick another winning portfolio in 2014? Find out which companies they've chosen for the 2014 Watchlist in this exclusive from The Life Sciences Report and Sagient Research.

Recent Quotes

"GALE's E39 is in early development for ovarian and endometrial cancers that overexpress folate-binding protein, an interesting target." (8/1/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Mara Goldstein More >

"GALE's NeuVax represents a new paradigm in treating patients." (5/10/13) Galena Biopharma Inc. - Mara Goldstein, Cantor Fitzgerald More >

"The NeuVax PRESENT trial will account for the largest component of GALE's future valuation." (1/31/13) Galena Biopharma Inc. - The Life Sciences Report Watchlist 2013 featuring Analyst Mara Goldstein More >

"GALE has an intriguing late-stage asset and is a story worth exploring." (12/10/12) Galena Biopharma Inc. - Mara Goldstein, Cantor Fitzgerald More >

"With an intriguing, late stage asset, GALE is worth exploring." (11/13/12) Galena Biopharma Inc. - Mara Goldstein, Cantor Fitzgerald More >

"GALE's modest valuation, late-stage assets and corporate profile are compelling." (8/15/12) Galena Biopharma Inc. - Mara Goldstein, Cantor Fitzgerald More >

"GALE is high-risk/high-reward with a relatively low valuation." (7/26/12) Galena Biopharma Inc. - The Life Sciences Report Interview with Mara Goldstein More >

"GALE is a story worth exploring, with milestone events forthcoming." (7/18/12) Galena Biopharma Inc. - Mara Goldstein, Cantor Fitzgerald More >



Due to permission requirements, not all quotes are shown.